- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Award-winning McKesson Patient Relationship Solutions on display at McKesson ideaShare 2013
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
PRINCETON, N.J. — Bristol-Myers Squibb said its late-stage clinical trial for a cancer treatment, which currently is under review by the Food and Drug Administration, achieved its primary endpoint.
The company said its phase-3 trial for investigational compound ipilimumab, designed for previously untreated patients that were diagnosed with metastatic melanoma, improved overall survival. The study compared the combination of ipilimumab 10 mg/kg and chemotherapy (dacarbazine) with chemotherapy alone.
The Prescription Drug User Fee Act date for the U.S. filing is March 26, Bristol said.